Angiotensin converting enzyme inhibitors or angiotensin receptors blockers equally enhances skeletal structure via different metabolic influence

Abstract

The impact of renin‐angiotensin system (RAS) on bone remodeling and metabolism has gained more interest in recent years, where several RAS metabolites are deemed as potential targets for skeletal diseases. This study compares the effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin‐II (AngII) type‐1 receptor (AT1R) blockers on bone structure and remodeling and investigates the involvement of neutral endopeptidase enzyme (NEP) and angiotensin 1‐9 (Ang1‐9) in ovariectomized (OVX) rats. OVX animals received either captopril or losartan for 6 weeks. Both antihypertensive agents equally attenuated the elevated levels of bone metabolic bio‐markers and restored Ca2+ and phosphorous renal elimination and bone deposition. The altered bone cortical and trabecular morphometry in OVX rats was similarly ameliorated. In femurs heads, the expressions of NEP and Ang1‐9 were enhanced by captopril, while remained unchanged in losartan groups. In addition, both drugs down‐regulated the osteoclastogenesis inducing factor, receptor activator NF‐κB ligand (RANKL), while enhanced osteoprotegerin. Although, both antihypertensive agents had different influence on local skeletal RAS metabolism, losartan and captopril equally restored bone micro‐structure in estrogen deficient animals.This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.